Plain-English translation of NCT06783166 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether dapagliflozin, a newer medication originally developed for diabetes, can help patients hospitalized with acute heart failure more effectively than acetazolamide, an older water pill. Both medications would be added to your standard heart failure treatment for 3 days. The study wants to see which one helps remove excess fluid from your body better and gets you out of the hospital sooner.
Acute heart failure causes dangerous fluid buildup in the body, and patients often spend a long time in the hospital recovering. Researchers want to find out if this medication can improve how well standard treatments work and help patients go home faster and feel better.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either dapagliflozin or acetazolamide as a once-daily pill for 3 days while you are in the hospital. This medication will be added to the water pills and other standard heart failure treatments your doctor is already giving you. Doctors will monitor how well the medication works and watch for any side effects throughout your hospital stay.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Egypt